Compare American Tower Corp (AMT) vs Bristol-Myers Squibb Co (BMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Tower Corp vs Bristol-Myers Squibb Co — how do they compare? American Tower Corp trades at $171.25 (market cap $79.00B), while Bristol-Myers Squibb Co trades at $63.7 (market cap $129.94B). The key difference: Bristol-Myers Squibb Co is the larger of the two by market cap, and American Tower Corp pays the higher dividend (4.12%). Which is the better fit depends on your goals.
| AMT | BMY | |
|---|---|---|
Market Cap | $79.00B | $129.94B |
Sector | Real Estate | Health |
52-Week High | $211.88 | $65.89 |
52-Week Low | $162.11 | $42.60 |
Enterprise Value | $122.53B | $163.92B |
Dividend Yield | 4.12% | 3.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American Tower Corporation (AMT) trades at $171.4, up 1.35% over the past 24 hours, with a bearish technical signal from moving averages but strong fundamental performance. The company reported Q2 2026 earnings beats, with EPS of $1.86 versus $1.57 expected, and maintains robust profitability margins, including a net income margin of 26.81%. Recent news highlights accelerated lease contract growth and a positive analyst consensus.
The outlook for AMT is supported by solid earnings growth and a 27.3% upside to the consensus price target of $206.17, though risks include interest rate sensitivity and high debt levels. Investment appeal hinges on execution in telecom infrastructure and data center expansion, balanced against macroeconomic pressures.
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Tower Corp
American Tower owns and operates more than 220,000 cell towers throughout the U.S., Asia, Latin America, Europe, and Africa. It also owns and/or operates 25 data centers in eight U.S. markets after acquiring CoreSite. On its towers, the company has a very concentrated customer base, with most revenue in each market being generated by just the top few mobile carriers. The company operates more than 40,000 towers in the U.S., which accounted for more than half of its total revenue in 2021. Outside the U.S., American Tower's greatest presence is in India and Brazil, where it operates roughly 75,000 and 19,000 towers, respectively. American Tower operates as a real estate investment trust.
Read more on AMT →About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →
